Evaluation of Oral ART6043 Alone and Combined with Olaparib in Patients With Advanced or Metastatic Solid Tumors Including Breast Cancer
Led by Artios Pharma Ltd · Updated on 2026-10-19
181
Participants Needed
27
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ART6043, an oral anti-cancer drug, alone or combined with the PARP inhibitor olaparib, in patients with advanced or metastatic solid tumors. The study focuses on cancers with DNA repair defects and includes patients with specific genetic mutations like germline BRCA in advanced breast cancer. The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary effectiveness of ART6043.
The study has two parts Part A includes dose escalation of ART6043 alone Part A1 and in combination with olaparib Part A2 for advanced cancers with DNA damage response gene defects. Part B is a dose-expansion phase comparing ART6043 plus olaparib against olaparib alone in patients with HER2-negative advanced breast cancer and germline BRCA mutations. Treatments are administered in 21-day cycles, and patients may continue therapy as long as clinical benefit is observed or until progression or unacceptable toxicity.
Participants will undergo regular assessments including monitoring for dose limiting toxicities during the first treatment cycle and progression-free survival over up to 3.7 years. Evaluations include adverse events, tumor response, changes in tumor size and cancer markers, pharmacokinetics, and overall survival. Safety is monitored throughout, with follow-up visits after treatment discontinuation. The total study duration may extend until disease progression or other stopping criteria are met.
CONDITIONS
Brief Title
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Research Team
A
Artios Pharma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
ART6043 alone
ART6043 + olaparib
Olaparib alone
Current standard treatment
What it is
Oral DNA polymerase theta (Polθ) inhibitor being tested alone in patients with advanced or metastatic solid tumors.
Oral Polθ inhibitor given together with the PARP inhibitor olaparib to exploit DNA damage response deficiencies.
Olaparib monotherapy used as comparator in the expansion cohort for HER2‑negative, gBRCA‑mutated breast cancer.
PARP inhibitors such as olaparib are a standard therapy option for patients with germline BRCA‑mutated, HER2‑negative metastatic breast cancer.
Dose‑escalation (Part A2) and dose‑expansion in combination with olaparib.
Comparator arm in dose‑expansion cohort (Part B2).
Provides comparison to treatments typically used outside this trial in the same disease setting.
Primary use
To establish safety, tolerability, pharmacokinetics and early signs of activity as a single agent.
To evaluate tolerability and preliminary efficacy when combined with olaparib in DDR‑deficient tumors.
Serve as comparator to assess combination effects in context of standard PARP inhibitor therapy.
Commonly used PARP inhibitor therapy outside clinical trials in this patient population.
How it is given or performed
ART6043 administered orally as single agent per protocol.
ART6043 and olaparib both administered orally in combination.
Olaparib administered orally alone as per comparator arm.
PARP inhibitors like olaparib are typically given orally in routine care.
Evidence status
Preclinical studies show potent Polθ inhibition and synthetic lethality in HR‑deficient tumor models.
Early clinical data indicate tolerability and promising activity in combination with olaparib in DDR‑deficient tumors.
Olaparib has demonstrated activity in BRCA‑mutated breast cancer as monotherapy.
PARP inhibitors are established to improve outcomes in patients with gBRCA‑mutated metastatic breast cancer.
Important limitations
Early‑phase data; efficacy and safety as single agent are not yet established in patients.
Combination findings are preliminary and from early cohorts with limited patient numbers.
Comparator arm may not reflect newer combination regimens emerging in practice.
Standard therapy benefit may be limited by acquired resistance or prior PARP inhibitor exposure.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients who have stopped all prior chemotherapy, non-hormonal targeted therapy, or investigational drugs for at least 21 days or 5 half-lives
Endocrine and hormonal cancer treatments stopped at least 7 days before study medication, except for prostate cancer
Completion of any palliative radiotherapy at least 14 days before randomization
Resolution of all toxicities from prior therapy or surgeries
Performance status of 0 to 2 on the ECOG scale
Adequate organ function
Use of highly effective contraception if of childbearing potential or with partners of childbearing potential
Estimated life expectancy of 12 weeks or more
For Part A1: advanced or metastatic cancer, preferably with DNA damage response gene mutations
For Part A2: advanced or metastatic cancer with DNA damage response gene mutations and suitable for PARP inhibitor treatment
For Part B: HER2-negative locally advanced or metastatic breast cancer with germline BRCA mutation, prior chemotherapy unless contraindicated, and no or limited prior PARP inhibitor treatment
You will not qualify if you...
Pregnancy
Diagnosis of myelodysplastic syndrome or acute myeloid leukemia, or features suggesting these
Ongoing interstitial lung disease or pneumonitis
Major gastrointestinal problems affecting absorption of study drugs
Receipt of live vaccine within 30 days before first study dose
Major surgery within 4 weeks before study entry
Significant bleeding disorder or vasculitis, or recent severe bleeding episode within 12 weeks
History of allergy or hypersensitivity to study drug components
For Part B: inflammatory breast cancer
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 3.7 years or until disease progression
Participants receive ART6043 orally as monotherapy or combined with olaparib in 21-day cycles, depending on their study group assignment. Treatment continues as long as clinical benefit lasts or until disease progression or unacceptable side effects.
Visits every 21 days for treatment cycles and regular monitoring
Follow-up
Duration - Up to 90 days after treatment discontinuation and ongoing survival follow-up
After treatment ends, participants are monitored for safety and response, including adverse event tracking and survival follow-up.
Periodic follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Phase 1a Study of H1710 Injection to Assess Safety and How It Works in Adults With Advanced Solid Tumors
Study of 177LuLu-XT117 Treatment in Adults With Advanced Solid Tumors Showing FAP Positivity
Evaluating Safety, Dosage, and Early Effectiveness
Study of 177LuLu-XT117 Injection to Assess Safety and Effectiveness in Patients With Advanced FAP-positive Solid Tumors
Phase 1 Study of 225AcAc-FAPI-XT Injection for Treating Advanced Solid Tumors in Adults
Phase I Study of CD70-targeted CAR-T Therapy for Adults with Advanced or Metastatic CD70-positive Solid Tumors
Phase I Study of Paclitaxel Cationic Liposomes Delivered by Arterial Infusion for Advanced Solid Tumors
Study of Purinostat Mesylate Injection in Combination Therapy for Advanced Solid Tumors
Evaluating Safety, Tolerability, and Early Effectiveness in Adults
Phase 1 Study to Assess Safety and Effectiveness of SPH7485 Tablets in Adults with Advanced Solid Tumors
Phase I Study of SYS6023 Given by Intravenous Infusion in Adults with Advanced Solid Tumors